329 related articles for article (PubMed ID: 19436199)
1. Desmoid tumor: from surgical extirpation to molecular dissection.
Lazar AJ; Hajibashi S; Lev D
Curr Opin Oncol; 2009 Jul; 21(4):352-9. PubMed ID: 19436199
[TBL] [Abstract][Full Text] [Related]
2. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors).
Lips DJ; Barker N; Clevers H; Hennipman A
Eur J Surg Oncol; 2009 Jan; 35(1):3-10. PubMed ID: 18722078
[TBL] [Abstract][Full Text] [Related]
3. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
[TBL] [Abstract][Full Text] [Related]
4. Optimizing treatment of desmoid tumors.
Lev D; Kotilingam D; Wei C; Ballo MT; Zagars GK; Pisters PW; Lazar AA; Patel SR; Benjamin RS; Pollock RE
J Clin Oncol; 2007 May; 25(13):1785-91. PubMed ID: 17470870
[TBL] [Abstract][Full Text] [Related]
5. Multimodality management of desmoid tumors: how important is a negative surgical margin?
Melis M; Zager JS; Sondak VK
J Surg Oncol; 2008 Dec; 98(8):594-602. PubMed ID: 19072851
[TBL] [Abstract][Full Text] [Related]
6. Desmoid tumors: need for an individualized approach.
de Bree E; Keus R; Melissas J; Tsiftsis D; van Coevorden F
Expert Rev Anticancer Ther; 2009 Apr; 9(4):525-35. PubMed ID: 19374605
[TBL] [Abstract][Full Text] [Related]
7. Correlation between beta-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors.
Matono H; Oda Y; Nakamori M; Tamiya S; Yamamoto H; Yokoyama R; Saito T; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2008 Dec; 39(12):1802-8. PubMed ID: 18715618
[TBL] [Abstract][Full Text] [Related]
8. Abdominal desmoid tumors.
Sakorafas GH; Nissotakis C; Peros G
Surg Oncol; 2007 Aug; 16(2):131-42. PubMed ID: 17719772
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in desmoid-type fibromatosis: a clinicopathological and immunohistochemical analysis of 46 cases.
Huang PW; Tzen CY
Pathology; 2010 Feb; 42(2):147-50. PubMed ID: 20085516
[TBL] [Abstract][Full Text] [Related]
10. Pediatric aggressive fibromatosis of the head and neck: a 20-year retrospective review.
Sharma A; Ngan BY; Sándor GK; Campisi P; Forte V
J Pediatr Surg; 2008 Sep; 43(9):1596-604. PubMed ID: 18778992
[TBL] [Abstract][Full Text] [Related]
11. Optimal therapy for desmoid tumors: current options and challenges for the future.
Al-Jazrawe M; Au M; Alman B
Expert Rev Anticancer Ther; 2015; 15(12):1443-58. PubMed ID: 26472625
[TBL] [Abstract][Full Text] [Related]
12. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.
Lazar AJ; Tuvin D; Hajibashi S; Habeeb S; Bolshakov S; Mayordomo-Aranda E; Warneke CL; Lopez-Terrada D; Pollock RE; Lev D
Am J Pathol; 2008 Nov; 173(5):1518-27. PubMed ID: 18832571
[TBL] [Abstract][Full Text] [Related]
13. Desmoid tumors and current status of management.
Hosalkar HS; Fox EJ; Delaney T; Torbert JT; Ogilvie CM; Lackman RD
Orthop Clin North Am; 2006 Jan; 37(1):53-63. PubMed ID: 16311111
[TBL] [Abstract][Full Text] [Related]
14. Aggressive fibromatosis (desmoid tumors): definition, occurrence, pathology, diagnostic problems, clinical behavior, genetic background.
Ferenc T; Sygut J; Kopczyński J; Mayer M; Latos-Bieleńska A; Dziki A; Kulig A
Pol J Pathol; 2006; 57(1):5-15. PubMed ID: 16739877
[TBL] [Abstract][Full Text] [Related]
15. Desmoid tumors: clinical features and treatment options for advanced disease.
Kasper B; Ströbel P; Hohenberger P
Oncologist; 2011; 16(5):682-93. PubMed ID: 21478276
[TBL] [Abstract][Full Text] [Related]
16. Analysis of APC, alpha-, beta-catenins, and N-cadherin protein expression in aggressive fibromatosis (desmoid tumor).
Ferenc T; Wroński JW; Kopczyński J; Kulig A; Sidor M; Stalińska L; Dziki A; Sygut J
Pathol Res Pract; 2009; 205(5):311-24. PubMed ID: 19124205
[TBL] [Abstract][Full Text] [Related]
17. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
[TBL] [Abstract][Full Text] [Related]
18. 'Difficult to diagnose' desmoid tumours: a potential role for CTNNB1 mutational analysis.
Colombo C; Bolshakov S; Hajibashi S; Lopez-Terrada L; Wang WL; Rao P; Benjamin RS; Lazar AJ; Lev D
Histopathology; 2011 Aug; 59(2):336-40. PubMed ID: 21884214
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.
Signoroni S; Frattini M; Negri T; Pastore E; Tamborini E; Casieri P; Orsenigo M; Da Riva L; Radice P; Sala P; Gronchi A; Bertario L; Pierotti MA; Pilotti S
Clin Cancer Res; 2007 Sep; 13(17):5034-40. PubMed ID: 17785554
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment for local control of extremity and trunk desmoid tumors.
Shido Y; Nishida Y; Nakashima H; Katagiri H; Sugiura H; Yamada Y; Ishiguro N
Arch Orthop Trauma Surg; 2009 Jul; 129(7):929-33. PubMed ID: 18810472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
